Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
PPCB · NASDAQ · Pharmaceutical Preparations
Propanc Biopharma (PPCB) · oqro.io/stocks/PPCB · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Propanc Biopharma was filed in the last 90 days. The latest on record was on Aug 23, 2012.
Since 2012, Propanc Biopharma insiders reported 1 open-market purchase and 5 sales on Forms 4 and 5, with purchases in 1 different year, most recently 2012.
No open-market sale by an insider of Propanc Biopharma (PPCB) was filed with the SEC in the last 90 days.
No trade in Propanc Biopharma (PPCB) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$1.78+0.055 (+3.19%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−99.1% (−$205.15) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $206.93 on Nov 20, 2025 to $1.78 on Nov 20, 2026 (−99.1%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Camberwell, Victoria, C3.
Last 12 months
−99.1%
Market value
$1.97M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 20K shares sold short (1.8% of shares outstanding), −60.9% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Notice of delisting or failure to meet listing rules
8-K on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Insiders of Propanc Biopharma reported 1 open-market purchase and 5 sales since 2012; purchases in 2012.
| Year | Bought | Sold |
|---|---|---|
| 2013 | — | $8K2×2 trades |
| 2012 | $50K1×1 trade | $52K3×3 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 5,000 words.
The Company was originally formed in Melbourne, Victoria, Australia on October 15, 2007, as Propanc PTY LTD. On November 23, 2010, Propanc Health Group Corporation was incorporated in the State of Delaware and in January 2011; to reorganize our Company, we acquired all the outstanding shares of Propanc PTY LTD on a one-for-one basis, whereby Propanc PTY LTD became our wholly owned subsidiary. Effective April 20, 2017, we changed our name to “Propanc Biopharma, Inc.” to better reflect our current stage of operations and development. We are a development-stage healthcare company that is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancer.
And 14 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Sep 25, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Revenue
—
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt $55K, cash —, at Mar 31, 2026
Net income, last 12 months
−$22.6M
Operating loss: profit did not cover interest
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO.
Latest annual report filed Sep 25, 2026. Read the filing
The risk factor headings of this report could not be read with confidence, so none are shown. They are in the filing.
We are not currently involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, or proceeding by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our Company or our subsidiary, threatened against or affecting our Company, our Common Stock, our subsidiary or of our companies or our subsidiary’s officers or directors in their capacities as such, in which an adverse decision could have a material adverse…
Source: SEC EDGAR, Form 10-K filed Sep 25, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Contracts, lobbying and filings
Company reports, price and press
Things to keep in mind
No Schedule 13D or 13G filing on PPCB over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Off-exchange trading: about 1.1 million shares a week traded away from the exchanges over the latest 4 published weeks, 50 thousand of them on ATS. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: CBX (18.0%), IBKR ATS (10.1%), LEVEL ATS (6.4%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others.